Diazepam (Valium) vs Midazolam (Nayzilam)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diazepam (Valium)
Marketed by Waylis Therapeutics LLC and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Midazolam (Nayzilam)
Marketed by UCB
NCT01390220 · Phase 3 · terminated
This was a randomized, triple-blind, placebo-controlled trial in 201 patients, and the primary outcome, control of a seizure cluster with no recurrence, was reached significantly more often with midazolam than with placebo (72 of 134 patients vs 23 of 67, p=0.011).
Reported efficacy
Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67 (met)
Result source: NCT01390220
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Diazepam (Valium) | Midazolam (Nayzilam) |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00621478 | —Not reported |
| 50% responder rate | —Not posted · NCT00621478 | —Not reported |
| Seizure freedom | —Not posted · NCT00621478 | 54.8% vs 38.7%+16.1 vs placeboNCT01999777 |
Seizure frequency, % change
- Diazepam (Valium)
- —Not posted · NCT00621478
- Midazolam (Nayzilam)
- —Not reported
50% responder rate
- Diazepam (Valium)
- —Not posted · NCT00621478
- Midazolam (Nayzilam)
- —Not reported
Seizure freedom
- Diazepam (Valium)
- —Not posted · NCT00621478
- Midazolam (Nayzilam)
- 54.8% vs 38.7%+16.1 vs placeboNCT01999777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Diazepam (Valium): 3 of 4 rows · Midazolam (Nayzilam): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Diazepam (Valium) | Midazolam (Nayzilam) |
|---|---|---|
| Dropout rate | 3.2%a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result76.5% NCT00326612 · Phase 2 · registry result, not featured evidence | —5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 31.2%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Discontinued due to AEs | —a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result— NCT00326612 · Phase 2 · registry result, not featured evidence | —5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results—5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 5.8%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 — NCT01999777 · Phase 3 · monotherapy |
| Serious AEs | 0%a NCT01417078 · Phase 2 · registry result, not featured evidence show 1 more result0% NCT00326612 · Phase 2 · registry result, not featured evidence | 0%5 mg + 5 mgb NCT01390220 · Phase 3 · Epilepsy · phase 3 show 4 more results0%5 mg only NCT01390220 · Phase 3 · Epilepsy · phase 3 —USL261 CP NCT01390220 · Phase 3 · Epilepsy · phase 3 0.7%USL261 TDP NCT01390220 · Phase 3 · Epilepsy · phase 3 0% NCT01999777 · Phase 3 · monotherapy |
| Most frequent reported AEs | a headache 51.6% dysgeusia 25.8% nasal discomfort 22.6% NCT01417078 · Phase 2 · registry result, not featured evidence | 5 mg + 5 mgb nasal discomfort 16.3% (placebo 7.3%) somnolence 9.3% (placebo 9.8%) throat irritation 7% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 show 3 more results5 mg only somnolence 9.9% (placebo 9.8%) headache 6.6% (placebo 0%) nasal discomfort 5.5% (placebo 7.3%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 7.3%) somnolence 9.6% (placebo 9.8%) lacrimation increased 6.8% (placebo 2.4%) NCT01390220 · Phase 3 · Epilepsy · phase 3 nasal discomfort 16.1% (placebo 16.1%) nausea 9.7% (placebo 3.2%) throat irritation 9.7% (placebo 9.7%) NCT01999777 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
- bPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Diazepam (Valium)
Midazolam (Nayzilam)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diazepam (Valium)'s landscape · Midazolam (Nayzilam)'s landscape